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AbsTRACT
Colorectal cancer (CRC) is one of the most common and 
lethal malignancies in Western countries. Its development 
is a multistep process that spans more than 15 years, 
thereby providing an opportunity for prevention and early 
detection. The high incidence and mortality rates emphasise 
the need for prevention and screening. Many countries 
have therefore introduced CRC screening programmes. It 
is expected, and preliminary evidence in some countries 
suggests, that this screening effort will decrease CRC- 
related mortality rates. CRC prevention involves a healthy 
lifestyle and chemoprevention—more specifically, oral 
chemoprevention that can interfere with progression 
from a normal colonic mucosa to adenocarcinoma. This 
preventive effect is important for individuals with a genetic 
predisposition, but also in the general population. The ideal 
chemopreventive agent, or combination of agents, remains 
unknown, especially when considering safety during long- 
term use. This review evaluates the evidence across 80 
meta- analyses of interventional and observational studies of 
CRC prevention using medications, vitamins, supplements 
and dietary factors. This review suggests that the following 
factors are associated with a decreased incidence of CRC: 
aspirin, non- steroidal anti- inflammatory drugs, magnesium, 
folate, a high consumption of fruits and vegetables, fibre and 
dairy products. An increased incidence of CRC was observed 
with frequent alcohol or meat consumption. No evidence of 
a protective effect for tea, coffee, garlic, fish and soy products 
was found. The level of evidence is moderate for aspirin, 
β-carotene and selenium, but is low or very low for all other 
exposures or interventions.
InTRoduCTIon
Colorectal cancer (CRC) remains the third most 
commonly diagnosed cancer among both men and 
women in the US,1 with a cumulative lifetime risk 
of developing CRC of 5% in the general popula-
tion.2 In the USA, it is the second leading cause 
of cancer- related deaths in men and the third in 
women.1 Its global burden is expected to increase 
by 60% to more than 2.2 million new cases and 
1.1 million cancer deaths by 2030.3 Whereas CRC 
mortality has been declining in most developed 
countries, diverging trends have been observed for 
incidence rates, with some countries having noted 
a decrease, such as in the USA, France or Japan, 
while others have reported an increase, such as in 
Canada, the UK or the Netherlands.3 As CRC has a 
natural history that spans over more than 15 years, 
from normal mucosa to overt cancer, it provides a 
window of opportunity for effective prevention.4
Randomised clinical trials (RCTs) have shown 
that biennial screening with faecal occult blood 
testing reduces mortality by 15% through the 
detection and subsequent removal of advanced 
adenomas or by diagnosing CRC at an early stage.5 
Nevertheless, there is a wide heterogeneity in 
screening uptake across countries (ranging from 
21% to 73%),6 and indeed across different popu-
lation groups, including heterogeneity according to 
socioeconomic factors.7 In addition to increasing 
screening uptake, promotion of a healthy lifestyle is 
of great importance.
The following work is an umbrella review of 
systematic reviews and meta- analyses of interven-
tions targeting chemopreventive products for CRC, 
specifically in an average- risk population.
MeThods
search strategy
We performed a systematic review searching Embase, 
Medline and ISI Web of Knowledge using a highly 
sensitive search strategy to identify meta- analyses 
or systematic reviews. The following combination 
of controlled vocabulary and text words, related to 
(1) colon or colorectal cancer (neoplasia, carcinoma, 
tumour, metastasis, malignancy) and (2) chemopre-
vention agents, were used, including medications 
(aspirin, non- steroidal anti- inflammatory drugs 
(NSAIDs), statin), vitamins or supplements (magne-
sium, calcium, folic acid, vitamin A, B, C, E, D, 
β-carotene and selenium), as well as dietary factors 
(coffee, tea, fish, dairy products, fibre, fruits and 
vegetables, meat and alcohol). All citations were inde-
pendently reviewed by two authors (MB and MM) 
and any discrepancies were resolved through discus-
sion. Recursive searches and cross- references were 
carried out using a 'similar articles' function and hand 
searches of identified articles.
study selection and patient population
We identified all meta- analyses assessing the risk of 
colon, rectal or colorectal cancer and chemopreven-
tion agents in an average- risk population. Any studies 
on specific high- risk populations, such as those with 
previous adenoma removal, diabetes mellitus, chronic 
inflammatory bowel disease or a genetic background 
that increases CRC risk, were excluded. We included 
all studies published in French or English between 
September 1980 and June 2019, and more specifically 
all meta- analyses that performed a complete systematic 
search of the literature coupled with a pooled anal-
ysis, with reported odds ratios (ORs), relative risks 
(RRs) or hazard ratios (HRs) and corresponding 95% 
 on F












2245Chapelle N, et al. Gut 2020;69:2244–2255. doi:10.1136/gutjnl-2020-320990
Recent advances in clinical practice
Figure 1 Quorum diagram. From: Moher D et al.97
confidence intervals (95% CIs). Meta- analyses that reported adjusted 
risk ratios (aRRs), or summary relative risk estimates (SRREs) were 
also included.
Data were extracted by two independent reviewers (NC and MM) 
with the following information: authors, year of publication, search 
string, databases searches and dates of search, study inclusion and 
exclusion criteria, outcomes, number and design of included studies, 
number of patients, measure and category of exposure or interven-
tion, type of cancer, study quality, heterogeneity, publication bias, 
effect size and 95% CI. Specific data for men and women, colon 
subsites and dose and/or duration of intake for each studied compo-
nent were also extracted, when available.
data analysis and quality assessment
Owing to the heterogeneity of the collected information and 
comparisons, the overall effect on the incidence of CRC was 
analysed qualitatively and categorised as protective or no effect. 
Chemoprotective agents were qualified as 'protective effect' if 
the included meta- analysis showed an overall significant effect 
for the primary outcome and 'no effect' if no statistical difference 
was noted. We used the GRADE (Grading of Recommendations, 
Assessment, Development and Evaluations) rating of evidence 
to characterise the evidence of the effect of each studied factor 
on colorectal cancer incidence.8 Information on quality scores, 
publication bias and heterogeneity was included. Heteroge-
neity reported in the included meta- analyses was considered 
as low, moderate or severe for I2 <25%, 25–75% and >75%, 
respectively. When an I2 value was not provided, heterogeneity 
was defined as significant or not, based on a p value below 
or above 0.05, respectively. The quality of each meta- analysis 
is reported using the PRISMA (Preferred Reporting Items for 
Systematic Reviews and Meta- Analyses) checklist for meta- 
analyses and the AMSTAR (assessment of multiple systematic 
reviews) checklist for systematic reviews (data available on 
request).
Patients and public involvement
This paper is a systematic review for which we did not identify a 
specific need for patient involvement.
Research ethics approval: human participants
This paper is a systematic review of already published articles. 
Ethics approval was considered unnecessary as ethics approval 
had been considered by the original publications.
ResulTs
From the 2063 records initially identified, 343 full text articles 
were assessed for eligibility; 80 articles were finally included in the 
qualitative analysis of this umbrella review (figure 1). Summary 
of results, with the GRADING of evidence, is presented sepa-
rately for medications, vitamins or nutrient supplements intake, 
any combination of vitamins and nutrient supplements, and for 
dietary factors (table 1). They have been classified according to 
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Table 1 Summary of results of each component
Component
number and type of meta- analyses
(reference) Grade of overall certainty of evidence
overall effect on colorectal 
cancer incidence
Range of the effect* 
(if significant)
Components with protective effect on CRC risk
  Aspirin 4 Observational,9–12 1 RCT,14 1 mixed13 ⨁⨁⨁◯
Moderate
(serious inconsistency and suspected publication bias)
Protective −14% to −29%
  Low- dose aspirin 2 Observational,10 12 1 RCT13 ⨁⨁◯◯
Low
(serious inconsistency and suspected publication bias)
Protective (observational)
No effect in RCT
  




(serious inconsistency and suspected publication bias)
Protective −27% to −43%
  Magnesium 3 Observational17–19 ⨁⨁◯◯
Low
Protective −11% to −22%
  Folic acid 3 Observational20–22 ⨁◯◯◯
Very low
(serious inconsistency and indirectness, strong 
suspected publication bias)
Protective −12% to −15%




  Dairy products 3 Observational26–28 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
Protective/no effect −13% to −19%
  Fibre 5 Observational26 29–32 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
Protective effect (4) no effect (1) −22% to −43%
  Fruits and vegetables 9 Observational26 30 33–39 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
Protective effect (5) no effect (4) −8% to −52%
  Soy 3 Observational38–40 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
Protective (2)/no effect (1) −8% to −15%
Components with no effect on CRC risk
  Vitamin E 5 RCT,41–45 2 observational21 22 ⨁⨁◯◯
Low
(serious indirectness)
No effect (6)/protective (1 Obs) −12%
  Vitamin C 2 Observational,21 22 1 RCT44 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
No effect NA
  Antioxidant 
combinations
4 RCT,41 42 44 45 1 observational21 ⨁◯◯◯
Very low
(very serious indirectness)
No effect (4)/protective (one obs, 
vitamin C combination)
−17%
  β-Carotene 3 RCT42 45 46 ⨁⨁⨁◯ Moderate
(serious inconsistency)
No effect NA
  β-Carotene 
combinations




  Selenium 3 RCT42 44 45 ⨁⨁⨁◯ Moderate No effect NA
  Tea 5 Observational26 48–51 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
No effect (4)/protective effect (1) −18%
  Garlic and allium 4 Observational21 52–54 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
No effect/protective (1) −24%
  Vitamin D 3 Observational,21 22 56 1 RCT55 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
No effect/Protective (2 Obs) −12% to −13%




Components with unclear effect on CRC risk
  Coffee 7 Observational26 58–63 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
No effect (4)/protective effect (3) −17% to −24%
  Fish and omega-3 7 Observational26 33 64–68 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
No effect (4)/Protective (3) −7% to −13%
Continued
 on F
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Component
number and type of meta- analyses
(reference) Grade of overall certainty of evidence
overall effect on colorectal 
cancer incidence
Range of the effect* 
(if significant)
  Calcium 3 Observational,21 72 73 2 RCT7071 ⨁◯◯◯
Very Low
(serious inconsistency and serious indirectness, serious 
imprecision)
Protective (observational)
No effect or increased risk (RCT)




  Vitamin A 2 Observational21 22 ⨁⨁◯◯
Low
(very serious indirectness)
Protective (1)/no effect (1)   
  Group B vitamins 2 Observational22 69 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
Protective (1)/no effect (1) −10% (Vitamin B6)
  Statins 6 Mixed,76–81 1 RCT,74 1 observational75 ⨁⨁◯◯
Low
(serious inconsistency and serious indirectness)
Unclear −6% to −14%
Components associated with increased CRC risk
  Meat 7 Observational26 33 39 82–85 ⨁◯◯◯
Very low
(serious inconsistency and very serious indirectness)
Increased risk +12% to +21%
  Alcohol 9 Observational86–94 ⨁◯◯◯
Very low
(serious inconsistency and indirectness, strong 
suspected publication bias)
Increased risk +12% to +20%
CRC, colorectal cancer; NA, Not applicable; NSAID, non- steroidal anti- inflammatory drug; RCT, randomised clinical trial.
Table 1 Continued
their effect on CRC prevention as (i) protective, (ii) no effect, 
(iii) unclear effect or (iv) increasing risk of CRC. The character-
istics and quality of included studies and the effect of each factor 
on CRC incidence are shown in table 2. Large variations were 
observed in quality, publication bias and between- study hetero-
geneity (table 2).
exposures or interventions associated with a protective 
effect on CRC prevention (supplementary table 1)
Aspirin
Six meta- analyses, published between 2006 and 2017, evaluated 
the effect of aspirin. Four pooled results of observational studies 
only,9–12 one assessed both RCTs and observational studies,13 and 
the last RCTs only.14 Aspirin dose, frequency and treatment dura-
tion were reported separately in the meta- analysis by Ye et al,12 
while the effect of low- dose aspirin (daily intake ≤325 mg/day) 
on CRC prevention was evaluated in three meta- analyses.10 12 13
A statistically significant protective effect of aspirin intake 
overall (RRs ranging from 0.71 to 0.86) was reported in the 
meta- analyses of both observational studies,9 11–13 and RCTs.14 
The magnitude of the protective effect was similar for colon 
cancer (RR=0.71 to 0.76) and rectal cancer (RR=0.68 to 0.74) 
when analysed separately.11 12 The protective effect in the colon 
may be limited to proximal colon cancers (RR=0.58; 95% CI 
0.46 to 0.74) as results for distal colon cancer did not reach 
statistical significance (RR=0.77, 95% CI 0.58 to 1.04).14 
Increases in dosing, frequency and duration of intake were all 
independently associated with a decreased risk (RR ranging from 
0.80 to 0.84), but were based on only one meta- analysis.12 Meta- 
analyses of low- dose aspirin (up to 325 mg/day) found conflicting 
results, with either no protective effect,13 or a protective effect 
for a daily intake of aspirin as low as 75 mg/day,10 with a possible 
dose–response effect and with RR ranging from 0.90 to 0.80 
for daily intakes ranging from 75 mg to 325 mg, respectively.12 
Heterogeneity within the meta- analysis was noted in two of the 
studies included (with one quantified as strong).9 11
Despite serious inconsistencies across the meta- analyses and 
possible publication bias, the level of overall certainty was 
graded as moderate since the meta- analyses that included RCTs 
reported the strongest effects.
Summary: Based on RCT and observational studies, aspirin 
is protective in most of the included meta- analyses, the rela-
tive risks range from 0.71 to 0.86. The protective effect may 
be observed even for doses as low as 75 mg/day, with a dose–
response effect reported up to 325 mg/day. Certainty of evidence 
is moderate.
Non-steroidal anti-inflammatory drugs (NSAIDs)
Three meta- analyses of observational studies published between 
2007 and 2018 were included.10 15 16 Overall, NSAID intake 
was associated with a protective effect against CRC (RR ranging 
from 0.57 to 0.74).10 15 16 The optimal duration for the observed 
protective effect of NSAIDs is uncertain, with two meta- analyses 
suggesting a need for an intake of at least 5 years,10 16 whereas 
the third, suggested a protective effect after the first year.10 
Moderate to strong heterogeneities were reported in only one 
meta- analysis.16 The level of overall certainty was graded low 
(table 2).
Summary: Based on observational studies, NSAID use is associ-
ated with a significant decrease in CRC incidence, with RR ranging 
from 0.57 to 0.74. The effect was consistently significant over n 
intake of at least 5 years. Certainty of evidence is low.
Magnesium
Three meta- analyses of observational studies compared the lowest 
with the highest level of magnesium intake (from dietary sources or 
supplements).17–19 All three meta- analyses found a protective effect 
against CRC (RR ranging from 0.78 to 0.87).17–19 A dose–response 
analysis was performed in two meta- analyses; one reported a RR 
of 0.93 (95% CI 0.88 to 0.99) for colon cancer for each incre-
mental intake of 50 mg/day,18 whereas the other found no statisti-
cally significant differences when assessing 100 mg/day increments, 
RR=0.87 (95% CI 0.75 to 1.01).17
Low to moderate heterogeneity was found within the three 
meta- analyses.17–19 The level of overall certainty was graded low 
(table 2).
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Table 2 Grading assessment of the certainty of evidence of each component
Certainty assessment Summary of findings
No of participants (studies) follow- up
Risk of bias Inconsistency Indirectness Imprecision Publication bias Overall certainty of evidence
Relative effect 
(95% CI)
Aspirin user compared with non- aspirin user in 
prevention of colorectal cancer
  6 Meta- analyses Not serious a Serious b Not serious c Not serious Publication bias 
strongly suspected d
⨁⨁⨁◯Moderate 0.71 to 0.86
Low dose aspirin user compared with control in 
prevention of colorectal cancer
  3 Meta- analyses Not serious Serious e Not serious Not serious Publication bias 
strongly suspected
⨁⨁◯◯Low 0.71 to 1.02
NSAIDs compared with no NSAIDs for prevention 
of colorectal cancer
  3 Meta- analyses Not serious Serious f Not serious Not serious Publication bias 
strongly suspected d
⨁⨁◯◯Low 0.57 to 0.74
Magnesium compared with control for prevention 
of colorectal cancer
  3 Meta- analyses Not serious Not serious Not serious g Not serious None ⨁⨁◯◯Low 0.78 to 0.89
Folic acid compared with control for prevention of 
colorectal cancer
  3 Meta- analyses Not serious Serious h serious i Not serious Publication bias 
strongly suspected j
⨁◯◯◯Very low 0.85 to 0.88
Folic acid in combination with other antioxidants 
for the chemoprevention of colorectal cancer
  3 Meta- analyses Not serious Not serious very serious k Not serious None ⨁◯◯◯Very low 0.96 to 1.15
Dairy products compared with control for 
prevention of colorectal cancer
  3 Meta- analyses Not serious Serious l very serious m Not serious None ⨁◯◯◯Very low 0.81 to 0.87
Fibre compared with control for prevention of 
colorectal cancer
5 Meta- analyses Not serious Serious n very serious m Not serious None ⨁◯◯◯Very low 0.57 to 0.94
Fruits and vegetables
  9 Meta- analyses Not serious Serious o very serious m Not serious None ⨁◯◯◯Very low 0.48 to 1.00
Soy products
  3 Meta- analyses Not serious Serious p very serious m Not serious None ⨁◯◯◯Very low 0.85 to 1.01
Vitamin E
  7 Meta- analyses Not serious Not serious serious m Not serious None ⨁⨁◯◯Low 0.82 to 1.05
Vitamin C
  3 Meta- analyses Not serious Serious q Very serious m Not serious None ⨁◯◯◯Very low 0.84 to 0.92
Combinations of vitamins A, C, E, D or 
antioxidants
  5 Meta- analyses Not serious Not serious Very serious m Not serious None ⨁◯◯◯Very low 0.92 to 1.00
β-Carotene
  3 Meta- analyses Not serious Serious r Not serious Not serious None ⨁⨁⨁◯Moderate 0.99 to 1.09
β-Carotene in combination with other products
  5 Meta- analyses Not serious Not serious Very serious s Not serious None ⨁◯◯◯Very low 0.96 to 1.15
Selenium
  3 Meta- analyses Not serious Not serious Not serious Not serious None ⨁⨁⨁◯Moderate 0.48 to 0.77
Tea
  5 Meta- analyses Not serious Serious t Very serious m Not serious None ⨁◯◯◯Very low 0.82 to 0.99
Garlic
  4 Meta- analyses Not serious Serious u Very serious m Not serious None ⨁◯◯◯Very low 1.03 to 1.24
Vitamin D
  4 Meta- analyses Not serious Serious v Very serious m Not serious None ⨁◯◯◯Very low 0.87 to 0.92
  2 Meta- analyses Not serious Not serious Very serious m Not serious None ⨁◯◯◯Very low 0.62 to 1.08
Coffee or caffeine
  7 Meta- analyses Not serious Serious w Very serious m Not serious None ⨁◯◯◯Very low 0.76 to 1.00
Fish and omega-3
  7 Meta- analyses Not serious Serious x Very serious m Not serious None ⨁◯◯◯Very low 0.88 to 1.03
Vitamin A
  2 Meta- analyses Not serious Not serious Very serious m Not serious None ⨁⨁◯◯Low 0.77 to 0.87
Vitamin B
  2 Meta- analyses Not serious Serious y Very serious m Not serious None ⨁◯◯◯Very low 0.86 to 1.18
Calcium
  5 Meta- analyses Not serious Serious z Serious aa Serious bb None ⨁◯◯◯Very low 0.34 to 1.38
Continued
 on F
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Certainty assessment Summary of findings
No of participants (studies) follow- up




  8 Meta- analyses Not serious Serious cc Serious dd Not serious None ⨁⨁◯◯Low 0.74 to 1.02
Meat
  7 Meta- analyses Not serious Serious ee Very serious m Not serious None ⨁◯◯◯Very low 1.04 to 1.25
Alcohol compared with control for prevention of 
colorectal cancer
  9 Meta- analyses Not serious Serious ff Serious gg Not serious Publication bias 
strongly suspected
⨁◯◯◯Very low 1.03 to 1.52
a. Source of bias was difficult to assess as included meta- analyses included observational studies and did not perform standard risk of bias tools nor any other biases.
b. Heterogeneity was noted in three of the five meta- analyses9 10 (only for case–control); and11, not reported in one13 and no heterogeneity noted in one.12
c. All meta- analyses, any dose aspirin definition.
d. Publication bias was detected but no value provided in the meta- analysis.
e. Heterogeneity was noted in one of the three meta- analyses,10 not reported in two.12 13
f. Heterogeneity was noted in one of the three meta- analyses,16 not reported in two.10 15
g. Intervention and control are based on highest category compared with lowest category of magnesium intake as opposed to primary question, similar quartiles.
h. Heterogeneity reported in one meta- analysis22 but not in two others.20 21
i. Intervention and control are based on different controls as well as high vs low intake.
j. Publication bias was detected in two meta- analyses.20 22
k. Different intervention and comparison within each meta- analysis included.
l. Heterogeneity found in one meta- analysis.27
m. Different intervention and comparison within each meta- analysis included.
n. Heterogeneity was reported in one meta- analysis30 none in two26 29 and not reported in one.31
o. Varying heterogeneity in meta- analyses.
p. Heterogeneity was noted in Zhu 2015.38
q. Strong heterogeneity was reported in one meta- analysis.21
r. Two meta- analyses reported heterogeneity42 46 and one did not report any results.45
s. Different intervention and comparison within each meta- analysis included.
t. Heterogeneity was reported in three meta- analyses26 50 51 but none in one.48
u. Heterogeneity was noted in one meta- analysis54.
v. Heterogeneity was reported in two meta- analyses21 22 none in one56 and not reported in another.55
w. Heterogeneity noted in five meta- analyses.58 60 26 61 63
x. Heterogeneity was noted in three meta- analyses,65 66 68 none was noted in four.26 33 64 67
y. Heterogeneity was found in one meta- analysis.69
z. Heterogeneity was noted in two meta- analyses,21 73 none was noted for three.70 71 72
aa. Intervention and control are based on different controls as well as high vs low intake.
bb. Imprecision due to wide confidence interval in one meta- analysis.70
cc. Heterogeneity was reported in two meta- analyses80 81 no heterogeneity in two,74 75 varying strength of heterogeneity between publication type in two77 78 or not reported in the last two meta- analyses.76 79
dd. Databases used in meta- analyses are population based therefore include all population, not only average- risk population.
ee. Heterogeneity was reported in two meta- analyses,82 84 not in five26 33 39 83 85.
ff. All included meta- analyses for this outcome reported heterogeneity.
gg. Different intervention and comparison within each meta- analysis included. Doses standard.
Table 2 Continued
Summary: Meta- analyses of observational studies suggest a 
significant protective effect associated with the highest versus 
lowest magnesium intake (RR ranging from 0.78 to 0.87). The 
effect was observed when at least 255 mg/day was consumed. 
Certainty of evidence is low.
Folic acid (vitamin B9)
Three meta- analyses of observational studies,20–22 were reviewed. 
All compared highest to lowest doses of folate intake, and found 
total (ie, dietary and supplement) folate intake to be associated 
with a protective effect against CRC (RR ranging from 0.85 to 
0.88).20–22 One meta- analysis provided results by cancer location 
(rectal or colon) and type of study (cohort or case–control). A 
protective effect for colon cancer was only described in a pooled 
analysis of nine cohort studies, (RR=0.75; 95% CI 0.57 to 0.99).20 
Heterogeneity within the meta- analyses was low,20 21 to moderate.22 
The overall certainty of evidence was graded very low.
Three meta- analyses published between 2010 and 2015, two 
including RCTs exclusively,23 24 and one combining RCTs with 
a cohort study,25 have evaluated the effect of folic acid (supple-
mentation of 0.4 mg/day, or 0.5 to 2.5 mg/day) combined with 
other vitamins or aspirin on CRC incidence (online supplemen-
tary table 2). No significant effect on CRC was observed in any 
of these meta- analyses. Heterogeneity was low in all studies.23–25 
The level of overall certainty was graded very low.
Summary: Based on meta- analyses of observational studies, high 
intake of folic acid is associated with a significant decrease in CRC 
risk (RR=0.85 to 0.88). A protective dose cannot be determined. 
However, meta- analyses of RCTs investigating folate in combination 
with various other components did not report any effect on CRC 
incidence. Certainty of evidence is very low.
Dairy products
Three meta- analyses of observational studies, published between 
2012 and 2017, were included.26–28 Results are presented below 
according to the type of dairy products investigated.
Aune et al27 reported a RR for CRC of 0.81 (95% CI 0.74 to 
0.90) associated with high versus low consumers of dairy prod-
ucts. The effect appeared to be dose related, with any 400 g/day 
increase being associated with a RR reduction of 0.83–0.87.26 27
The protective effect persisted when the analysis was restricted 
to milk consumption, both for CRC as a whole (RR=0.83; 
95% CI 0.74 to 0.93) and colon cancer in particular (RR=0.82; 
95% CI 0.72 to 0.94), but not rectal cancer.27 A similar protec-
tive effect against CRC (RR=0.85; 95% CI 0.77 to 0.93) was 
reported in high consumers of non- fermented milk.28 The effect 
was statistically significant in men (RR=0.79; 95% CI 0.69 to 
0.93) but not in women (RR=0.83; 95% CI 0.68 to 1.02).28 In a 
dose–response analysis, RRs ranged from 0.90 to 0.94 for CRC 
and from 0.92 to 0.93 for colon cancer alone, both for a 200 g/
day increase of milk consumption.26 27 For rectal cancer, only 
one of the two meta- analyses showed a statistically significant 
protective effect (RR=0.94; 95% CI 0.91 to 0.97).27
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None of the meta- analyses described a protective effect associ-
ated with cheese consumption.26–28
Heterogeneity was low to moderate in all the meta- analyses. 
The level of overall certainty was graded very low.
Summary: Based on observational studies, consumption 
of dairy products is associated with a decrease in CRC risk 
(RR=0.81 to 0.87). However, the small number of available 
meta- analyses, and the multiplicity of outcomes and variety 
of dairy products do not allow any confident conclusion to 
be reached about dose or duration necessary for protection. 
Certainty of evidence is very low.
Fibres
Five meta- analyses of observational studies published between 
1990 and 2018 were included.26 29–32
The highest intakes of total dietary fibres showed a protective 
effect against CRC (RR ranging from 0.57 to 0.88).29 30 One 
meta- analysis focused on colon cancer only and also reported a 
significant protective effect (RR=0.82; 95% CI 0.73 to 0.92).32 
Each incremental 10 g/day of whole grain consumption was asso-
ciated with a significant risk reduction in both CRC (RR ranging 
from 0.83 to 0.90),26 29 and colon cancer (RR=0.82; 95% CI 
0.73 to 0.92).26 Significant heterogeneity was reported in three 
studies.29 30 32 The level of overall certainty was graded very low.
Summary: Based on observational studies, fibre consumption 
is associated with a significant reduction in CRC risk, ranging 
from 0.57 to 0.78. Nevertheless, optimal daily dose and dura-
tion of intake cannot be defined due to significant heterogeneity 
across studies. Certainty of evidence is very low.
Fruits and vegetables
Nine meta- analyses published from 1990 to 2017, all of observa-
tional studies only, were included.26 30 33–39 Results are presented 
below according to the type of fruit and/or vegetable investigated.
Considered altogether, high consumption of fruits and 
vegetables was associated with a significant decreased risk in 
both colorectal (RR=0.92; 95% CI 0.86 to 0.99) and colon 
(RR=0.91; 95% CI 0.84 to 0.99) cancers in one meta- analysis.34
High fruit consumption was associated with a protective 
effect for both CRC (RR=0.90; 95% CI 0.83 to 0.98) and colon 
cancer (RR=0.89; 95% CI 0.81 to 0.98), but not for rectal 
cancer (RR=0.91; 95% CI 0.76 to 1.09).34 Conflicting results 
were reported by Huxley et al, where the only significant effect 
was found for rectal cancer (RR=0.78; 95% CI 0.63 to 0.97), 
but not colorectal (RR=0.99; 95% CI 0.90 to 1.08) or colon 
cancer (RR=1.01; 95% CI 0.86; 1.18).33
Three of six meta- analyses reported a significantly decreased 
CRC risk in those having high vegetables intake,30 34 37 (RR 
ranging from 0.48 to 0.91); the other three meta- analyses found 
no statistically significant effects.33 36 39 Two of the four meta- 
analyses reported significant protective effects for colon cancer 
(RR ranging from 0.84 to 0.87),34 36 but none for rectal cancer.
A significant dose–effect against CRC was found for any 
100 g/day incremental fruit and vegetable intake (RR=0.98; 
95% CI 0.97 to 0.99), and for vegetable intake only (RR=0.90; 
95% CI 0.85 to 0.95),34 (RR=0.98; 95% CI 0.96 to 0.99).26 For 
the fruit consumption dose–effect analysis, controversial results 
have been reported. Indeed, a significant dose–effect for any 
increment of 100 g/day was reported by Aune et al34 (RR=0.89; 
95% CI 0.81 to 0.98), whereas results from Vieira et al26 failed 
to reach statistical significance either for CRC, colon cancer or 
rectal cancer.
High consumption of legume, cabbage and cruciferous vegeta-
bles was associated with a significantly decreased CRC risk (RR 
ranging from 0.76 to 0.91).35 38 However, no effect was found in 
the dose–response analysis for legume consumption.26
Heterogeneity was reported to be low to moderate,26 35–39 or 
low.30 33 34 The overall level of certainty was graded very low.
Summary: Several meta- analyses of observational studies 
suggest a protective effect of fruit and/or vegetable consump-
tion against CRC risk, with RR ranging from 0.48 to 0.92, with 
also an incremental benefit for any 100 g/day incremental intake. 
More specific conclusions about type, dose and duration cannot 
be made. Certainty of evidence is very low.
Soy
Three meta- analyses of observational studies were published 
between 2014 and 2016.38–40 A significant protective effect of soy 
or soybean consumption against CRC was reported in two meta- 
analyses (RR=0.85; 95% CI 0.73 to 0.99),38 and (OR=0.92; 95% 
CI 0.87 to 0.97)40, whereas another reported no significant effect.39 
The noted beneficial effect was significant for colon (OR=0.92; 
95% CI 0.96 to 0.99) but not rectal cancer.40
Heterogeneity was low to moderate.38 40 The level of overall 
certainty was graded very low.
Summary: Observational studies suggest a modest but signifi-
cant decrease in colon cancer risk associated with soy consump-
tion (RR=0.85 to 0.92). Certainty of evidence is very low
Components with no protective effect on CRC prevention 
(suPPleMenTARY TAble 2)
Vitamin E
Seven meta- analyses, five including RCTs only,41–45 and two 
comprising cohort studies,21 22 were published between 2007 
and 2015, investigating the effects of vitamin E consumption 
on CRC risk.
None of the studies reported any significant effect of vitamin 
E intake on CRC. Only one meta- analysis of five cohort studies 
comparing highest with lowest intake reported a significant 
protective effect against colon cancer (RR=0.82; 95% CI 0.67 
to 0.99).21 Heterogeneity was low to moderate in all the meta- 
analyses. The level of overall certainty was graded low.
Summary: RCT and observational studies suggest that vitamin 
E supplementation is not protective for CRC. Certainty of 
evidence is low.
Vitamin C
Three meta- analyses, two of observational studies only,21 22 and 
one of RCTs,44 published between 2011 and 2015, investigated 
the effect of vitamin C consumption on CRC prevention.
No protective effect of vitamin C intake on CRC or colon 
cancer risk was shown in any of the meta- analyses.21 22 44
Heterogeneity was low in the study by Papaioannou et al,44 
moderate in Liu et al,22 and strong in Heine- Bröring et al.21 The 
level of overall certainty was graded very low.
Summary: RCT and observational studies do not suggest a 
protective effect of vitamin C in CRC prevention. Certainty of 
evidence is very low
Antioxidants combination or combination of vitamins with other 
components
Five meta- analyses, four of RCTs only,41 42 44 45 and one of 
cohort studies,21 were published between 2007 and 2015. These 
investigated antioxidants or vitamin combinations with other 
components.
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Only one of these five meta- analyses reported a significant 
protective effect of multivitamin supplementation on CRC risk 
(RR=0.92; 95% CI 0.86 to 0.98).21
Heterogeneity was low in four of the meta- analyses,21 42 44 45 
and not reported in the fifth.41 The level of overall certainty was 
graded very low.
Summary: RCT and observational studies do not suggest that 
multivitamin intake, either alone or in combination with other 
components, exerts a protective effect on CRC risk. Certainty of 
evidence is very low.
β-Carotene
Eight meta- analyses of RCT published between 2004 and 2013 
have been included. Among them, three assessed β-carotene 
alone42 45 46 and five β-carotene in combination with other 
supplements or medication, including aspirin and various 'other 
components' (such as vitamin C, selenium or vitamin E).42 44–47
None of the pooled analyses, overall or by subgroups 
(according to gender or incremental dosing), found any signif-
icant protective effect of β-carotene consumption alone, or in 
association with other agents, on CRC risk.
Heterogeneity was strong in one study,46 moderate in two 
others,42 44 and not provided in the two others.45 47 The level of 
overall certainty was graded moderate for β-carotene alone and 
very low for β-carotene in combination.
Summary: Meta- analyses of RCTs provide no evidence 
to support the use of β-carotene, either alone or in combina-
tion with other products, in the primary prevention of CRC. 
Certainty of evidence is moderate for β-carotene alone and very 
low for β-carotene in combination.
Selenium
The effect of selenium supplementation on CRC risk was 
assessed in three meta- analyses of RCTs.42 44 45
None of the meta- analyses showed any significant effect of 
selenium on CRC incidence, either taken alone or in combina-
tion with other agents.
Heterogeneity was moderate in Papaioannou et al,44 low in 
Pais et al45 and not assessed in the Bjelakovic et al.42 The level of 
overall certainty was graded moderate.
Summary: Meta- analytical data of RCT suggest no protec-
tive effect of selenium on CRC risk. Certainty of evidence is 
moderate.
Products noted to have an unclear effect on CRC prevention 
(suPPleMenTARY TAble 3)
Tea
Five meta- analyses of observational studies published between 
2006 and 2017 were reviewed.26 48–51
Overall, high tea consumption (green, black and mixed tea) 
was not associated with a significant protective effect for CRC in 
two meta- analyses.49 50 Two meta- analyses investigated he effect 
of green tea consumption on CRC risk, with the first reporting a 
significant effect,51 but not the second.48
In subsite analysis, the protective effect was found in rectal 
cancer only (OR=0.91; 95% CI 0.85 to 0.99).50 In gender 
subgroup analysis, high consumption of tea and black tea (1 to 
5 cups/day) were both reported to be protective against CRC 
in women (OR=0.86; 95% CI 0.78 to 0.9450 and OR=0.82; 
95% CI 0.70 to 0.95,51 for any type of tea and black tea, respec-
tively). In the three remaining meta- analyses, no protective effect 
of tea consumption was reported.26 48 49
Heterogeneity was moderate in three studies,48–50 strong in 
one26 and significant in the last two.42 51 The level of overall 
certainty was graded very low.
Summary: Conclusions from meta- analyses of observational 
studies are disparate, with the effect of tea consumption on CRC 
risk remaining unclear. Certainty of evidence is very low.
Allium and garlic
Four meta- analyses of observational studies, published between 
2013 and 2014, investigated the role of allium vegetable, and 
garlic consumption, or garlic supplementation in CRC preven-
tion.21 52–54
When the effect of allium and garlic as a whole was assessed, 
no protective effect was reported. However, when studied sepa-
rately, one meta- analysis found that garlic and onion consump-
tion were both associated with a significant CRC risk reduction 
(RR=0.76; 95% CI 0.67 to 0.85 and RR=0.74; 95% CI 0.56 
to 0.98, for garlic and onion, respectively), and garlic alone 
with a decreased incidence of rectal cancer (RR=0.76; 95% CI 
0.59 to 0.98).54 Study heterogeneity was moderate in one meta- 
analysis,54 and low in the others.21 52 53 The level of overall 
certainty was graded very low.
Summary: Meta- analyses of observational studies yield dispa-
rate results to support any protective effect of allium and garlic 
consumption on CRC incidence. Certainty of evidence is very 
low.
Vitamin D
Four meta- analyses, published between 2011 and 2015, evalu-
ated the effect of vitamin D on CRC prevention. One included 
RCTs only,55 and three assessed observational studies only.21 22 56
Two of the meta- analyses of observational studies, comparing 
the highest with the lowest range of vitamin D intake, reported 
significant CRC risk reductions (RR ranging from 0.87 to 
0.88).22 56 Conversely, no significant protective effect was 
reported by the third meta- analysis of observational studies,21 
nor the meta- analysis of RCTs only.55
None of two meta- analyses of RCT investigating the combina-
tion of vitamin D and calcium reported a significant protective 
effect on CRC incidence.55 57
Heterogeneity was low56 to moderate,21 22 57 or not reported 
in one meta- analysis.55 The level of overall certainty was graded 
very low.
Summary: Meta- analyses of RCTs and observational studies 
yield disparate results to support any protective effect for 
vitamin D alone or in combination with calcium in CRC preven-
tion. Certainty of evidence is very low.
Coffee and caffeine
Seven meta- analyses of observational studies, published between 
1998 and 2017, assessed coffee or caffeine intake and CRC 
risk.26 58–63
Four of the seven meta- analyses reported no significant 
protective effect associated with coffee consumption on CRC 
risk.26 59 61–63 Two others reported a significant decrease in CRC 
risk among drinkers versus no drinkers (OR=0.83; 95% CI 
0.73 to 0.95),60 or drinkers of greatest versus lowest volumes 
(RR=0.76; 95% CI 0.66 to 0.89).58 The seventh meta- analysis 
by Li et al61 reported a significant protective association for 
the colon cancer subgroup (OR=0.79; 95% CI 0.67 to 0.95), 
whereas the effect was not significant in rectal cancer.
Among the three meta- analyses that performed a dose–
response analysis,26 60 63 one reported a protective association 
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for an incremental consumption of 1 cup/day on CRC, as well 
as on colon and rectal cancer when analysed individually (OR 
ranging from 0.94 to 0.97).60 The second reported a protec-
tive association for an incremental consumption of 6 to 8 cups/
day (RR ranging from 0.87 to 0.93),63 while the third found no 
significant association.26
Heterogeneity was low in one meta- analysis,59 moderate in 
three,26 61 63 high in two meta- analyses58 60 and not reported in 
the last study.62 The level of overall certainty was graded very 
low.
Summary: Meta- analyses of observational studies and site- 
specific subgroup analyses yield disparate results for any protec-
tive effect for coffee and caffeine intake in CRC prevention. 
Certainty of evidence is very low.
Fish and omega-3
Seven meta- analyses of observational studies published between 
2007 and 2017 were reviewed.26 33 64–68
In two of these, fish consumption was associated with a 
significant CRC risk reduction (RR ranging from 0.87 to 0.93) 
compared with non-/lowest- consumers.65 68 A protective effect 
was also observed for rectal cancer (RR=0.79; 95% CI 0.65 
to 0.97 and RR=0.85; 95% CI 0.75 to 0.95),65 68 and colon 
cancer alone (RR=0.95; 95% CI 0.91 to 0.98).68 In a third 
meta- analysis, the results were significant when assessing the 
pooled results of case–control studies (OR 0.83 to 0.84) but not 
of cohort studies.67 Three other meta- analyses did not report 
any significant associations when comparing highest and lowest 
consumption of fish or omega-3 fatty acids.33 64 66 In a dose–
response analysis of the seventh meta- analysis, any incremental 
100 mg/day of fish consumption was associated with a signifi-
cant decrease in CRC risk (RR=0.89; 95% CI 0.80 to 0.99), but 
the protective effect was lost when colon or rectal cancers were 
assessed separately.26 None of the other meta- analyses reporting 
incremental levels of fish consumption (20 g/day once a week 
and 100 g/week) found any significant dose–response protective 
effects on CRC.64 68
Heterogeneity was low in four meta- analyses,26 33 64 67 
moderate in two66 68 and significant in the last.65 The level of 
overall certainty was graded very low.
Summary: Meta- analyses of observational studies and site- 
specific subgroup analyses yield disparate results to support any 
protective effect for fish and omega-3 consumption in CRC 
prevention. Certainty of evidence is very low.
Vitamin A
Two meta- analyses of observational studies evaluating the asso-
ciation between vitamin A consumption and CRC,22 or colon 
cancer risk,21 were published in 2015.
No significant association was found when comparing low 
intake with high intake of vitamin A either for CRC or colon 
cancer sites.21 22 However, a significant protective association 
for colon cancer was found when comparing any vitamin A 
consumption with no intake (RR=0.77; 95% CI 0.62 to 
0.94).21
There was no heterogeneity in any of the meta- analyses. The 
level of overall certainty was graded low.
Summary: Two meta- analyses of observational studies 
yielded inconsistent results when assessing any protective effect 
of vitamin A intake in CRC chemoprevention. Certainty of 
evidence is low.
Vitamin B group (folic acid excluded)
Two meta- analyses of observational studies, published in 2010 
and 2015, were reviewed, one assessing intake of vitamin B2, 
vitamin B3, vitamin B6 and vitamin B12,22 while the second 
focused exclusively on vitamin B6 intake.69 The first meta- 
analysis compared highest with lowest intake, and noted that 
vitamin B2 and vitamin B6 were associated with a decreased risk 
of CRC (RR=0.86; 95% CI 0.76 to 0.97 and RR=0.88; 95% CI 
0.79 to 0.99 for vitamins B2 and B6, respectively).22 The second 
meta- analysis did not suggest any protective effect associated 
with vitamin B6 consumption.69
Heterogeneity was reported as moderate,22 or strong.69 The 
level of certainty was graded very low.
Summary: Two meta- analyses of observational studies yielded 
inconsistent results for any protective effect of the intake of vita-
mins B in CRC chemoprevention. Certainty of evidence is very 
low.
Calcium
Five meta- analyses published between 2008 and 2015 were 
reviewed, two of RCTs only,70 71 and three of observational 
studies.21 72 73
No significant effect of overall calcium supplementation 
on CRC incidence was reported in the meta- analyses that 
included two RCTs,70 and seven RCTs71 (study- level analysis), 
but an increased CRC risk (HR=1.63; 95% CI 1.01 to 2.64) 
was reported in patients receiving more than 500 mg/day of 
calcium supplementation in the results of four RCTs at a patient- 
level analysis.71 In contrast, a significant protective association 
was reported in two meta- analyses of observational studies 
(RR=0.76; 95% CI 0.65 to 0.89) and (RR=0.86; 95% CI 
0.79 to 0.95).21 72 An association with decreased CRC risk was 
noted for calcium dose ingestion for every 300 mg/day increase 
(RR=0.91; 95% CI 0.86 to 0.98).73
Heterogeneity was moderate in two meta- analyses,21 73 and 
low in the others.70–72 The level of overall certainty was graded 
very low.
Summary: Although a modest protective effect on CRC inci-
dence was found in observational studies of increased calcium 
ingestion, no protective effect, and even an increased CRC risk 
was reported in a meta- analysis of RCTs. Certainty of evidence 
is very low.
Statins
Eight meta- analyses, published between 2006 and 2014 were 
reviewed, one of RCT only,74 two of observational studies 
only75 76 and five that included RCTs and observational 
studies.77–81
None of the meta- analyses with pooled results of RCTs 
reported any significant protective effect of statin consump-
tion on CRC incidence as compared with placebo or no treat-
ment.74 75 77 78 80 81 In contrast, significant risk reductions of 
CRC were observed in pooled results of meta- analyses assessing 
only case–control or cohort studies (RR ranging from 0.86 to 
0.92).77 78 80 81 and in pooled results grouping both RCTs and 
observational studies (RR 0.90 and 0.91).80 81
Heterogeneity was low to moderate in the pooled analyses 
of RCTs,74 77 78 80 81 while moderate or strong heterogeneity 
was reported in the meta- analyses comprising observational 
studies,75 78 80 81 except for one reporting low heterogeneity.77 
The level of overall certainty was graded low.
Summary: Disparate evidence exists for any protective effect 
of statin administration on CRC risk. Although meta- analyses of 
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observational studies suggest a protective association, no bene-
ficial effect was noted in meta- analyses of RCTs. Certainty of 
evidence is low.
Products yielding a consistent increased risk of CRC 
(suPPleMenTARY TAble 4)
Meat
Seven meta- analyses of observational studies, published between 
2001 and 2017, assessed meat/fat animal consumption on CRC 
risk.26 33 39 82–85
A large amount of meat consumption and incremental 100 g/
day of total meat consumption were both significantly associated 
with an increased CRC risk (RR ranging from 1.21 to 1.25).39 82
High versus low red meat intake was significantly associated 
with increased CRC risk (RR ranging from 1.12 to 1.21).26 33 84 85 
A similar effect was also reported for incremental intakes of 
100 g/day of red meat, and for each incremental serving of meat 
per day (RR=1.12; 95% CI 1.00 to 1.25),26 OR=1.30; 95% 
CI 1.13 to 1.49),82 and each incremental serving per week 
(SRRE=1.02; 95% CI 1.00 to 1.0484). An increased associa-
tion with colon cancer was also noted (RR ranging from 1.11 to 
1.22),26 33 84 85 whereas only one meta- analysis suggested such a 
deleterious association for rectal cancer (RR=1.28; 95% CI 1.02 
to 1.60).33
In two meta- analyses a significantly increased association 
was reported between processed meat consumption and CRC 
(RR=1.17 to 1.1933 85), or colon cancer risks (RR=1.21 to 
1.23)33 85). Each incremental intake of 50 g/day of processed 
meat led to significant increases in CRC, colon and rectal cancer 
risks (RR ranging from 1.08 to 1.23), the magnitude of the asso-
ciation being greatest for colon cancer.26
In contradiction to red and processed meat consumption, a 
significant risk reduction in rectal cancer (RR=0.80; 95% CI 
0.67 to 0.96) was reported for high versus low consumers of 
poultry.85 No dose–effect was found in the meta- analysis by 
Vieira et al26 for any of cancer location.
No significant effect was reported with animal fat or protein 
intake.83
Heterogeneity was low to moderate in two meta analyses26 39 
and reported as 'significant' in two others.82 84 The level of overall 
certainty was graded very low.
Summary: Most of the available meta- analyses of observa-
tional studies report a significant association (RR ranging from 
1.12 to 1.21) between meat consumption (particularly red and 
processed) and increased CRC incidence. Dose–effect studies 
report a 10–30% increased risk for each increment of 100 g/day 
of total or red meat, with no clear limit threshold identifiable. 
Certainty of evidence is very low.
Alcohol
Nine meta- analyses of observational studies, published between 
1990 and 2015, were reviewed.86–94
Three meta- analyses comparing no/occasional drinkers with 
regular drinkers showed a significant increase in CRC risk (RR 
ranging from 1.12 to 1.20).90 93 94 Investigating a dose–effect and 
considering the no/occasional drinkers as controls, the lowest 
ingestion category of drinking (≤1 drink/day) was associated 
with a modest but significant increase in CRC risk (RR=1.07; 
95% CI 1.02 to 1.13) in one meta- analysis.93 A clear dose–effect 
relationship was reported in the meta- analysis of Bagnardi et al,88 
in which the RR for CRC increased with alcohol consumption 
(from 1.08 to 1.38 for daily intake of 25 g to 100 g, respectively).
For moderate drinkers (daily intake of two drinks, up to 25 g/
day of alcohol), two meta- analyses reported a significant asso-
ciation between alcohol intake and CRC risk (RR from 1.08 to 
1.10).86 88 With intakes of 2–3 drinks/day (12.6 g/day) up to 50 g/
day, all meta- analyses consistently reported a significant increase 
of CRC risk (RR between 1.17 and 1.23).88 90 92 93
Higher relative risks were reported in the highest exposure 
categories (heavy drinkers >4 drinks/day, more than 50 g/day) 
(RR ranging from 1.38 to 1.53).88 90 92–94 The relative risk for 
rectal cancer tended to be greater than for colon cancer.86–94
When stratified by gender, significant increases in CRC risk 
were observed for men only.90 93 When assessed, the risk for 
CRC in men increased proportionally to the amount of alcohol 
intake.90 92 93
Heterogeneity was moderate or 'significant' in all the meta- 
analyses.86–94 The level of overall certainty was graded very low.
Summary: Alcohol intake is associated with a significantly 
increased risk of CRC. The effect is dose- dependent and appears 
even at the lowest consumption doses investigated (1–2 drinks/
day). For similar intakes, men tend to have greater CRC risk. 
Certainty of evidence is very low.
ConClusIons
This contemporary umbrella review has confirmed decreased 
CRC incidences associated with some CRC chemopreventive 
agents, such as aspirin, NSAIDS, magnesium, folate, dairy prod-
ucts, fibre, soy or fruits and vegetables, suggesting that their use 
should be encouraged to reduce CRC incidence in average- risk 
individuals. On the other hand, meat consumption and alcohol 
intake were associated with increased CRC risks in almost all 
the meta- analyses published. Nevertheless, it should be kept 
in mind that the level of evidence is low or very low in most 
cases, mainly due to marked heterogeneity across published 
studies, and the type of study. Furthermore, in most cases, we 
were unable to identify an optimal dose and duration of expo-
sure/intake for any of the products, even in the case of low- 
dose aspirin and other compounds that have been extensively 
assessed. Although the present study synthesises the available 
data in the literature for chemoprevention of CRC, even in the 
case where all the meta- analyses provide congruent data (going 
in the same direction, whether protective or deleterious for the 
occurrence of CRC), the aforementioned limitations prevent 
us from providing high level of evidence for the consumption 
of any of the medications, vitamins, supplements and dietary 
factors discussed.
Since colorectal carcinogenesis is a process that spans several 
years or decades,95 designing RCTs specifically to assess the 
prevention of CRC in an average- risk population may not be 
feasible, and the effects of many molecules and foods can be 
studied only using long- term follow- up cohorts or case control 
studies—and this despite the difficulties in adjusting for many 
confounders as is needed in these types of studies that are more 
subject to bias. Additionally, in most of the RCTs, CRC incidence 
was usually not the primary endpoint of the trial (probably 
owing to feasibility and sample size considerations), while the 
populations investigated probably do not reflect a true general 
population, as patients known to be at a greater risk were often 
excluded.
The adverse events implications of any recommendations for 
large populations need also be considered and may outweigh 
benefits with regards to CRC incidence, such as has been the 
case in guidelines that have moved away from primary preven-
tion of cardiovascular disease using ASA.96
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We were not able to identify any subgroups in the general 
population that would particularly benefit or suffer from a 
particular chemopreventive agent owing to the average- risk 
population targeted, and the source data availability of stratified 
analyses above and beyond what we report.
One major limitation of the present umbrella meta- analysis 
was the impossibility of pooling the results of the different meta- 
analyses included for each component because of high between- 
study heterogeneity for patient selection, dosing and duration of 
exposure or intervention, follow- up time, and type of molecule/
food investigated. Although we proceeded systematically for 
every agent, grading of the evidence is usually performed for 
meta- analyses based on pooled estimates and therefore was not 
fully applicable in the present case. It is important for readers 
to understand that we completed an umbrella meta- analysis 
of published meta- analyses. We did not perform a systematic 
review of recent RCTs which may have been published after the 
end date of our literature review (2019).
It is our hope that despite all aforementioned limitations, this 
comprehensive umbrella meta- analysis will assist clinicians in 
counselling patients, and help to guide the future research on the 
topic that is required in many instances, to better characterise 
the impact of a nutritional, supplement, or chemical intervention 
in CRC prevention in an average- risk population.
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